The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Laboratory Corporation of America Holdings

NYSE: LH
Last

(U.S.) $139.56

Today's change+1.05 +0.76%
Updated July 29 4:04 PM EDT. Delayed by at least 15 minutes.
 

Laboratory Corporation of America Holdings

NYSE: LH
Last

(U.S.) $139.56

Today's change+1.05 +0.76%
Updated July 29 4:04 PM EDT. Delayed by at least 15 minutes.

Laboratory Corporation of America Holdings up (U.S.)$1.05

Laboratory Corporation of America Holdings closed up Friday by (U.S.)$1.05 or 0.76% to (U.S.)$139.56. Over the last five days, shares have gained 0.53% and 12.88% year to date. Shares have outperformed the S&P 500 by 7.40% during the last year.

Key company metrics

  • Open(U.S.) $138.29
  • Previous close(U.S.) $138.51
  • High(U.S.) $139.64
  • Low(U.S.) $137.98
  • Bid / Ask-- / --
  • YTD % change+12.88%
  • Volume810,187
  • Average volume (10-day)793,816
  • Average volume (1-month)965,472
  • Average volume (3-month)900,563
  • 52-week range(U.S.) $97.79 to (U.S.) $139.80
  • Beta0.87
  • Trailing P/E23.06×
  • P/E 1 year forward15.83×
  • Forward PEG1.57×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $6.05
Updated July 29 4:04 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+6.65%

Based on its net profit margin of 6.65%, Laboratory Corporation of America Holdings is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.21%Sector:HealthcareIndustry:Healthcare Facilities

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue2,4312,3682,3012,317
Total other revenue--------
Total revenue2,4312,3682,3012,317
Gross profit827777741763
Total cost of revenue1,6041,5911,5601,554
Total operating expense2,0642,0662,0572,010
Selling / general / administrative408412405383
Research & development--------
Depreciation / amortization45443847
Interest expense (income), net operating--------
Unusual expense (income)7195426
Other operating expenses, total--------
Operating income367302243307
Interest income (expense), net non-operating-54-55-57-56
Gain (loss) on sale of assets--------
Other--------
Income before tax313256186250
Income after tax199161115153
Income tax, total115967297
Net income198160114153
Total adjustments to net income--------
Net income before extra. items198160114153
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items198160114153
Inc. avail. to common incl. extra. items198160114153
Diluted net income198161114153
Dilution adjustment00--0
Diluted weighted average shares104104103103
Diluted EPS excluding extraordinary itemsvalue per share1.911.551.111.48
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share1.951.671.431.64